The loss of Aerie Pharmaceuticals under GAAP for 9 months of 2020 amounted to $136.964 million, which is 5.2% lower compared to $144.517 million in the previous year. Revenue increased by 29.2% to $58.455 million against $45.231 million a year earlier.